BIO Letter to POTUS on U.S./China Trade
The following letter was sent to the President of the United States in response to talks between the U.S. and China related to trade.
We were encouraged to learn of the results of your recent meeting with President Xi of the People’s Republic of China. The Biotechnology Innovation Organization (BIO) represents a broad swath of American companies that are globally competitive, but are denied a level playing field in China, and thus we welcome the news that the two sides have begun talks to address important structural issues, including forced technology transfer, intellectual property protection, and agriculture. These issues are of prime importance to BIO’s members and the future of the U.S. economy. As the negotiations commence, resolving systemic barriers to timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S. biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.